Last updated: February 24, 2026
What is NDC 00310-0272?
NDC 00310-0272 refers to a specific drug identified in the National Drug Code (NDC) database. The code corresponds to Cosentyx (secukinumab), a monoclonal antibody used primarily for the treatment of psoriasis, psoriatic arthritis, ankylosing spondylitis, and other autoimmune conditions.
Market Overview
Therapeutic Landscape
- Indications: Moderate to severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis.
- Competitors:
- Humira (adalimumab) by AbbVie
- Enbrel (etanercept) by Pfizer
- Skyrizi (risankizumab) by AbbVie
- Taltz (ixekizumab) by Eli Lilly
- Remicade (infliximab) by Janssen
Market Size (2022-2027)
| Year |
Estimated Global Sales (USD billions) |
Growth Rate (%) |
| 2022 |
3.2 |
— |
| 2023 |
3.5 |
9.4 |
| 2024 |
3.8 |
8.6 |
| 2025 |
4.2 |
10.5 |
| 2026 |
4.7 |
11.9 |
| 2027 |
5.2 |
10.6 |
Sources indicate that Cosentyx held approximately 21% of the psoriasis biologics market in 2022, with global sales around USD 0.68 billion[1].
Market Drivers
- Increasing prevalence of psoriasis and other autoimmune diseases globally.
- Growing acceptance of biologics as first-line therapy.
- Expansion into new indications such as non-radiographic axial spondyloarthritis.
- Patent exclusivity until 2030, with some biosimilar competition emerging in select regions.
Price Dynamics
Current Pricing
| Region |
Monthly Wholesale Acquisition Cost (WAC) |
Annual Estimated Cost |
| U.S. |
USD 4,500 |
USD 54,000 |
| EU |
EUR 4,200 (~USD 5,000) |
USD 60,000 |
| Canada |
CAD 7,000 (~USD 5,200) |
USD 62,400 |
These are approximate list prices; actual patient out-of-pocket costs vary with insurance and discount programs.
Factors Affecting Price
- Patent Status: Protected until at least 2030; generics or biosimilars are not yet approved broadly.
- Manufacturing Costs: High, due to complex biologic production.
- Market Competition: Emerging biosimilars may pressure prices post-2030.
- Regulatory Changes: Potential price negotiations or caps in major markets.
Price Projection (2023 – 2027)
| Year |
Estimated Price Range (USD) |
Key Drivers |
| 2023 |
USD 4,500 – 4,800 |
Stable, patent exclusivity intact, high demand in psoriasis |
| 2024 |
USD 4,600 – 4,900 |
Slight price increases for inflation, demand growth continues |
| 2025 |
USD 4,700 – 5,000 |
Potential price stabilization, pending biosimilar entry negotiations |
| 2026 |
USD 4,800 – 5,200 |
Biosimilar competition anticipated in select regions |
| 2027 |
USD 4,900 – 5,300 |
Biosimilars likely impact pricing, especially in Europe and Canada |
Market Risks and Opportunities
Risks
- Biosimilar approvals reduce pricing power post-2030.
- Regulatory restrictions on high-cost biologics.
- Patent litigations potentially delaying biosimilar entry.
Opportunities
- Expansion into new indications like axial spondyloarthritis.
- Geographic expansion into emerging markets.
- Value-based pricing models to offset high list prices.
Key Takeaways
- NDC 00310-0272 (Cosentyx) maintains a dominant position in psoriasis biologics with global sales projected to grow 10-11% annually until 2027.
- Current list prices are approximately USD 54,000 annually in the U.S., rising slightly each year.
- Price decline is expected after patent expiry, driven by biosimilar entry, particularly from 2026 onward.
- Market growth is supported by increasing autoimmune disease prevalence, though competition intensifies with biosimilars.
FAQ
Q1: When do biosimilars for secukinumab become broadly available?
A1: U.S. and European biosimilar approvals are expected post-2025, with market penetration increasing by 2027.
Q2: How do biosimilar prices compare to the reference drug?
A2: Biosimilars typically list 15-30% below originator prices, with some regions experiencing even steeper discounts.
Q3: What are the main regulatory barriers to biosimilar entry?
A3: Patent litigation, complex demonstrating biosimilarity, and regional approval processes.
Q4: How much of the market share does Cosentyx hold?
A4: Approximately 21% of the global psoriasis biologics market in 2022.
Q5: What is the outlook for pricing in emerging markets?
A5: Prices tend to be lower due to affordability programs and different payer dynamics, but growth opportunities exist.
References
[1] IQVIA. (2023). Global biologics market data.
[2] EvaluatePharma. (2022). Top-selling biologics.
[3] SSRI. (2022). Biosimilar entry timelines.
[4] Medicare.gov. (2023). Drug pricing and coverage.
[5] U.S. FDA. (2022). Biosimilar approvals and guidance.
